MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension

Completed
Conditions
Hypertension
Interventions
Drug: Telmisartan
First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
6336
Registration Number
NCT02242838

Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Placebo
Drug: BEA 2180 BR
Drug: Tiotropium
First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
37
Registration Number
NCT02242279

Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients

Completed
Conditions
Hypertension
Interventions
Drug: Telmisartan
First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
5018
Registration Number
NCT02242851

Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure

Completed
Conditions
Hypertension
Interventions
Drug: Micardis®
Drug: MicardisPlus®
First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1527
Registration Number
NCT02242864

Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension

First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
13248
Registration Number
NCT02242383

Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort

Phase 3
Completed
Conditions
Abdominal Pain
Interventions
Drug: Hyoscine Butylbromide - Tablet
Drug: Hyoscine Butylbromide - Capsule
Drug: Placebo
First Posted Date
2014-09-17
Last Posted Date
2017-07-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
302
Registration Number
NCT02242305

Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension

Phase 2
Completed
Conditions
Hypertension
Interventions
Drug: Placebo
Drug: Telmisartan
First Posted Date
2014-09-17
Last Posted Date
2017-12-28
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
77
Registration Number
NCT02242344

Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Low dose of telmisartan
Drug: High dose of telmisartan
First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
3045
Registration Number
NCT02242370

Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Valsartan
Drug: Telmisartan
Drug: Placebo
First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
440
Registration Number
NCT02242318

Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension

Phase 4
Terminated
Conditions
Hypertension
Interventions
Drug: Metoprolol succinate
Drug: Telmisartan
Drug: Placebo
First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02242812
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy